Ultra-rare disease specialist Ultragenyx Pharmaceutical (Nasdaq: RARE) has inked a deal with GeneTx Biotherapeutics in relation to the antisense oligonucleotide GTX-102.
The firms have agreed to collaborate on the development of GTX-102, which is designed to suppress the expression of the UBE3A-AS gene, as a possible treatment for Angelman syndrome.
Ultragenyx will make an upfront payment of $20 million for an exclusive option to acquire GeneTx, any time prior to 30 days after the Food and Drug Administration accepts an investigational new drug (IND) for GTX-102. The option period can be extended for an additional $25 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze